F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8674-8683

  Winer, Ira ^a   Wang, Shouyan ^a   Lee, Youg Eun Koo ^a   Fan, Wenzhe ^a   Gong, Yusong ^b   Burgos Ojeda, Daniela ^b   Spahlinger, Greg ^b   Kopelman, R ^a   Buckanovich, Ronald J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO ACID; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; F3 PROTEIN; PLATINUM; POLYACRYLAMIDE; UNCLASSIFIED DRUG; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOSENSITIVITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY TEST; DRUG BINDING; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYDROGEL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; TERATOMA; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UREA BLOOD LEVEL; VASCULAR NECROSIS; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROGEL; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAPERITONEAL; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; SURVIVAL RATE; TERATOMA; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78449299667     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1917     Document Type: Article

References (31)

1. Aghajanian C. The role of bevacizumab in ovarian cancer-an evolving story. Gynecol Oncol 2006;102:131-3.
2. Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 2006;102:5-7.
3. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.[see comment]. Gynecol Oncol 2006;102:140-4.
4. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006;102:425-8.
5. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
6. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006;102:134-9.
7. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911-20.
8. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007; 25:852-61.
9. Lu C, Bonome T, Li Y, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007;67:1757-68.
10. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005;8:381-402.
11. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radio-labeled α(v)β(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
12. Garde SV, Forte AJ, Ge M, et al. Binding and internalization of NGR-peptide- targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007;18:1189-200.
13. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003;163:871-8.
14. Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006;12:6677-86.
15. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A 2002; 99:7444-9.
16. Koo YE, Reddy GR, Bhojani M, et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006;58:1556-77.
17. Kopelman R, Koo YEL, Philbert M, et al. Multifunctional nanoparticle platforms for in vivo MRI enhancement and photodynamic therapy of a rat brain cancer. J Magn Magn Mater 2005;293:404-10.
18. Mukhopadhyay S, Barnes CM, Haskel A, Short SM, Barnes KR, Lippard SJ. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem 2008;19:39-49.
19. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther 2008;327:673-82.
20. Pastorino F, Di Paolo D, Piccardi F, et al. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 2008;14:7320-9.
21. Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009; 16:510-20.
22. Tzukerman M, Rosenberg T, Reiter I, et al. The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts. Cancer Res 2006;66:3792-801.
23. Tzukerman M, Rosenberg T, Ravel Y, Reiter I, Coleman R, Skorecki K. An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2003;100:13507-12.
24. Pulaski HL, Spahlinger G, Silva IA, et al. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009;7:49.
25. Conejo-Garcia JR, Buckanovich RJ, Benencia F, et al. Vascular leukocytes contribute to tumor vascularization. Blood 2005;105: 679-81.
26. Koo YE, Fan W, Hah H, et al. Photonic explorers based on multi-functional nanoplatforms for biosensing and photodynamic therapy. Appl Opt 2007;46:1924-30.
27. Jin W, Xu P, Zhan Y, et al. Degradable cisplatin-releasing core-shell nanogels from zwitterionic poly(β -aminoester)-graft-PEG for cancer chemotherapy. Drug Deliv 2007;14:279-86.
28. Uchino H, Matsumura Y, Negishi T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005;93:678-87.
29. Nishiyama N, Okazaki S, Cabral H, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003;63:8977-83.
30. Zhang L, Yang N, Garcia JR, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002;161:2295-309.
31. McLean K, Pulaski HS, Wang Y, Spahlinger G, Nor JE, Buckanovich RJ. Development of a mouse ovarian cancer model with human tumor vessels to test novel anti-vascular therapeutics. Gynecol Oncol 2009;112:S10-1.